As regenerative medicine technology centered on stem cells rapidly advances, there’s growing pressure in Korea to streamline the path from research to clinical application and commercialization.
The key challenge is balancing speed with safety. Experts unanimously agree that while promising treatments should be fast-tracked to patients, a robust system for long-term monitoring of effects and side effects is crucial.
Major countries like the U.S. and Japan have implemented expedited development and approval systems tailored to regenerative medicine. While Korea is expanding support through the Advanced Regenerative Medicine and Biopharmaceuticals Act, industry insiders argue for further refinement to accelerate the transition from promising technologies to clinical trials, approval, and treatment.
Japan and the U.S. both support expedited approval systems, and Korea is following suit by increasing its full-cycle support budget.
According to a comprehensive News1 report on Thursday, Japan has a system allowing preliminary approval for regenerative medicine products deemed safe and potentially effective, under specific conditions and timeframes.
Post-approval, companies must gather additional efficacy and safety data through real-world use. This conditional approval typically lasts up to seven years, during which companies must collect further data for reapplication.
The U.S. operates the Regenerative Medicine Advanced Therapy (RMAT) designation, supporting rapid development of cell and gene therapies showing early clinical promise for serious or life-threatening diseases.
Korea has established a fast-track system for advanced biopharmaceuticals. The government aims to accelerate the transition of research-stage regenerative medicine technologies to clinical applications through increased financial support.
The Ministry of Health and Welfare’s 2027 budget proposal allocates 30.2 billion KRW (21.8 million USD) for full-cycle support to bridge foundational technologies with clinical applications. It earmarks 26 billion KRW (about 18.8 million USD) for clinical research on next-generation gene and cell therapies and 6.3 billion KRW (about 4.5 million USD) for new bio artificial tissue research.
Park So-ra, head of the Regenerative Medicine Promotion Foundation, emphasizes that growing regenerative medicine into a viable industry requires expanding the market connecting clinical research, treatment, and commercialization.
Park explains that the Advanced Regenerative Medicine and Biopharmaceuticals Act operates on two pillars: the Ministry of Health and Welfare manages clinical research and treatment, while the Ministry of Food and Drug Safety oversees approval and commercialization of advanced biopharmaceuticals. This law should foster market growth enabling domestic treatment options, reducing the need for patients to seek treatment abroad.
Treatment Approval Is Not The End; Patient Data Serves As a Second Clinical Trial
Experts caution that rapid market entry should not compromise verification standards. This is particularly crucial for rare and intractable diseases where large-scale clinical trials are challenging. The focus should be on expediting treatment opportunities while continuously verifying effectiveness and safety during actual use.
A national-level regenerative medicine data system is essential for this purpose. Stem cell treatment doesn’t end with cell administration; ongoing monitoring is necessary to track cell types, dosages, post-treatment changes, and potential adverse reactions.
Basic safety management measures are already in place domestically. The Advanced Regenerative Medicine and Biopharmaceuticals Act mandates safety management organizations to collect and manage implementation data and conduct long-term follow-up studies when necessary.
Advanced biopharmaceuticals, including cell therapies like stem cells, can be designated for long-term follow-up. The Ministry of Food and Drug Safety and Korea Institute of Drug Safety and Risk Management oversee administration records and long-term adverse event occurrences through a dedicated system.
Moving forward, it’s crucial to utilize this accumulating data not just for patient safety but also for developing new treatments.
Standardizing treatment data across hospitals enables comparison of treatment efficacy for specific patient groups. Companies can leverage this for subsequent clinical trials and drug development, while regulators can use it to assess new treatments’ safety and efficacy.
In regenerative medicine, often targeting rare and intractable diseases, even single-patient data is valuable. For diseases where large-scale trials are unfeasible, connecting real-world data (RWD) from multiple institutions is vital to verify long-term effects and side effects.
This requires standardizing outcome and adverse event reporting across hospitals and establishing long-term patient tracking systems. Criteria for using data in research and regulation while protecting privacy are also necessary.
Rapid approvals alone are insufficient; entry should be swift, but management must be thorough.
Critics warn against lowering treatment barriers solely to grow the industry. Given high patient expectations for stem cells, there’s a risk of proliferating unproven treatments.
It’s particularly challenging for patients to distinguish between approved advanced biopharmaceuticals, regenerative medicine treatments, and unregulated “stem cell procedures” in general clinics.
Industry development and patient protection should be interconnected within a single system, not viewed as separate goals.
Promising technologies should receive early government support for clinical and approval strategies. Once safety and therapeutic potential are confirmed, patient access should be enhanced. Post-treatment, continuous monitoring of effectiveness and adverse reactions is crucial.
Proven effective technologies should progress to further trials or formal approvals, while those showing insufficient efficacy or unexpected risks should be halted or restricted.
Product quality control is critical. Cell-based treatments must demonstrate not only safety and efficacy but also consistent, reliable cell production.
Japan’s conditional approval system isn’t about approve first, verify later. It allows faster market entry but requires additional data gathering within a set timeframe for subsequent verification.
Park advises that for regenerative medicine to evolve from lab technology to a thriving industry, it needs more than company capabilities. It must build an ecosystem where hospitals, companies, and regulators collaborate on clinical and treatment data, informing research and regulatory decisions.
The competitiveness of Korean regenerative medicine doesn’t hinge on choosing between patient safety and industry growth.
Korea’s next challenge in the global regenerative medicine race is creating a system that accelerates treatment access and market growth while rigorously verifying the effectiveness and safety of patient treatments.